AI Summary
✦ ClarthaValuation Metrics
Trading 4.9% below historical median. Valuation is declining — currently in the undervalued zone (z-score: -0.24). Confidence: 81%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
0.22
Current
0.24
Overvalued
0.25
Undervalued
0.18
5Y Average
49.73
Current
50.50
Overvalued
58.10
Undervalued
44.28
5Y Average
31.06
Current
32.04
Overvalued
34.67
Undervalued
26.48
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
JIO FIN SERVICES LTD JIOFINConsumer Finance | +208.2% | 55.0% | 79.1x Premium | +173% vs avg | -21.6% |
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.9x Premium | +17% vs avg | +10.6% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Premium | +30% vs avg | -15.6% |
MUTHOOT FINANCE LIMITED MUTHOOTFINConsumer Finance | +35.3% | 55.5% | 10.3x Undervalued | -64% vs avg | +11.6% |
INDIAN RENEWABLE ENERGY IREDASpecialized Finance | +23.7% | 46.0% | 17.1x Undervalued | -41% vs avg | -17.3% |
SHRIRAM FINANCE LIMITED SHRIRAMFINConsumer Finance | +39.1% | 50.1% | 20.1x Undervalued | -31% vs avg | +80.5% |
TATA CAPITAL LIMITED TATACAPConsumer Finance | +40.3% | 39.7% | 28.7x Fair | -1% vs avg | +12.0% |
POWER FIN CORP LTD. PFCSpecialized Finance | +0.8% | 54.5% | 4.9x Undervalued | -83% vs avg | +0.3% |
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.9x Undervalued | -19% vs avg | +10.6% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | -9% vs avg | -15.6% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Fair | -15% vs avg | +11.2% |
GLAXOSMITHKLINE PHARMA LT GLAXOPharmaceuticals | +16.6% | 27.0% | 41.2x Fair | -1% vs avg | -3.3% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | -7% vs avg | +31.7% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +120% vs avg | +121.8% |
AUROBINDO PHARMA LTD AUROPHARMAPharmaceuticals | +16.3% | 10.6% | 25.8x Undervalued | -38% vs avg | +57.5% |
ALKEM LABORATORIES LTD. ALKEMPharmaceuticals | +14.6% | 15.6% | 29.0x Undervalued | -30% vs avg | +16.0% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.33 CrMar 2026Latest net profit
₹0.26 CrMar 2026Free cash flow
₹6.00 CrMar 2026Net Profit
₹0.26 CrProfit conversionPerformance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue + | 4.70 | 5.48 | 0.76 | 1.20 | 8.10 | 0.45 | 6.79 | 0.62 | 6.07 | 0.42 | 8.59 | 9.52 | 1.33 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Expenses + | 0.51 | 0.49 | 0.54 | 0.49 | 0.85 | 0.76 | 0.84 | 0.69 | 0.83 | 0.71 | 0.68 | 0.80 | 0.97 |
| Financing Profit | 4.19 | 4.99 | 0.22 | 0.71 | 7.25 | -0.31 | 5.95 | -0.07 | 5.24 | -0.29 | 7.91 | 8.72 | 0.36 |
| Financing Margin % | 89.15% | 91.06% | 28.95% | 59.17% | 89.51% | -68.89% | 87.63% | -11.29% | 86.33% | -69.05% | 92.08% | 91.60% | 27.07% |
| Other Income + | -0.00 | -0.00 | -0.00 | 0.01 | -0.00 | -0.00 | 0.01 | 0.04 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Profit before tax | 4.19 | 4.99 | 0.22 | 0.72 | 7.25 | -0.31 | 5.96 | -0.03 | 5.24 | -0.29 | 7.91 | 8.72 | 0.36 |
| Tax % | 34.13% | 25.45% | 22.73% | 34.72% | 22.76% | -9.68% | 26.01% | -1,200.00% | 23.28% | 17.24% | 23.77% | 25.57% | 27.78% |
| Net Profit + | 2.76 | 3.73 | 0.16 | 0.47 | 5.60 | -0.28 | 4.41 | 0.34 | 4.01 | -0.35 | 6.03 | 6.49 | 0.26 |
| EPS in Rs | 11.23 | 15.18 | 0.65 | 1.91 | 22.79 | -1.14 | 17.95 | 1.38 | 13.57 | -1.18 | 20.41 | 21.96 | 0.88 |
| Gross NPA % | |||||||||||||
| Net NPA % | |||||||||||||
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).